Levolta Pharmaceuticals Presents Phase II Study Results for Potential Osteoarthritis Therapy at ACR Annual Meeting
18. November 2014 11:00 ET
|
Levolta Pharmaceuticals, Inc.
BETHLEHEM, Pa., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Levolta Pharmaceuticals, Inc. today presented the results of an exploratory Phase II study for a potential disease modifying drug for patients with...
Levolta Pharmaceuticals Receives U.S. Patent for Novel Investigational Therapy for Controlling Osteoarthritis
30. Oktober 2014 10:54 ET
|
Levolta Pharmaceuticals, Inc.
BETHLEHEM, Pa., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Levolta Pharmaceuticals, Inc., an emerging leader in developmental osteoarthritis (OA) therapy, announced today that the U.S. Patent and Trademark...